Announcements and Notices - [Results of EGM/SGM]

RemeGen Co., Ltd. operates biotechnology businesses. The Company develops therapeutic antibody drugs such as antibody drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies and double antibodies. RemeGen provides solutions autoimmune diseases, tumor diseases, and ophthalmic diseases.

Poll Results Of The 2025 Third
Extraordinary General Meeting

Proxy Form For Use
At The 2025 Third Extraordinary General Meeting

Announcements and Notices - [Notice of EGM/SGM / Closure of Books or Change of Book Closure Period]

Notice Of 2025 Third Extraordinary General Meeting

(1) Day-To-Day Related Party Transactions
For The Years 2026 To 2028
 (2) Proposed Amendments To Governance Policies
And
Notice Of 2025 Third Extraordinary General Meeting

Announcements and Notices - [Discloseable Transaction]

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Remegen (9995 HK)

Poll Results Of The 2025 Third Extraordinary General Meeting

Proxy Form For Use At The 2025 Third Extraordinary General Meeting

Notice Of 2025 Third Extraordinary General Meeting

(1) Day-To-Day Related Party Transactions For The Years 2026 To 2028 (2) Proposed Amendments To Governance Policies And Notice Of 2025 Third Extraordinary General Meeting

Discloseable Transaction - Purchase Of Wealth Management Product

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)